Virginia Fisher

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Meagan Montesion, Karthikeyan Murugesan, Dexter X. Jin et al. · Cancer Discovery · 2020 · 248 citations · Full text

Medicine, Immunology, Oncology +17

Diurnal Variation of Proliferative Activity in the Human Bone Marrow

Alvin M. Mauer, Virginia Fisher, Ruth Scheib · Blood · 1965 · 128 citations · Full text

Life Sciences, Cell Biology, Physiology +9

Characteristics of Cell Proliferation in Four Patients with Untreated Acute Leukemia

Alvin M. Mauer, Virginia Fisher · Blood · 1966 · 101 citations · Full text

Medicine, Cell Biology, Hematology +14

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer

Ryon P. Graf, Virginia Fisher, Janick Weberpals et al. · JAMA Network Open · 2022 · 88 citations · Full text

Medicine, Biostatistics, Oncology +17

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in <i>De Novo</i> Metastatic Castration-Sensitive Prostate Cancer

Umang Swami, Ryon P. Graf, Roberto Nussenzveig et al. · Clinical Cancer Research · 2022 · 68 citations

Medicine, Oncology, Urology +17